RxDoctor Payments Data

Christopher Redden, NP

Family · El Reno, OKNPI 1689984452

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 146 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$595
  • Otsuka America Pharmaceutical, Inc.$218
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$144
  • Novo Nordisk$139
  • Boehringer Ingelheim$139
  • Pfizer$137
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,405 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$54,549
Medicare patients
122
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide205$240,227
OzempicSemaglutide54$63,915
EliquisApixaban53$32,496
JardianceEmpagliflozin31$29,801
Tresiba Flextouch U-200Insulin Degludec20$27,797
FarxigaDapagliflozin Propanediol39$22,922
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$21,180
XareltoRivaroxaban15$17,653
TrulicityDulaglutide15$15,278
LinzessLinaclotide25$13,596
ShingrixVaricella-Zoster Ge/As01b/Pf48$10,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,818
JanuviaSitagliptin Phosphate13$9,600
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$8,306
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$57$255,504220 claims
Novo NordiskOzempic$139$63,91554 claims
AstraZenecaFarxiga, Breztri Aerosphere$44$44,10370 claims
PfizerEliquis$137$32,49653 claims
Boehringer IngelheimJardiance$139$29,80131 claims
GSKShingrix, Trelegy Ellipta, Arexvy$118$27,27085 claims
Johnson & JohnsonXarelto$20$17,65315 claims
AbbVieLinzess$595$13,59625 claims
MerckJanuvia$40$9,60013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in El Reno

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →